Insulin-sensitising agents

Bibliography

• ALBERTI KGMM, HOCKADAY TDR: Diabetes mellitus. In: Oxford Textbook of Medicine (2nd Edition). Weatherall et al. (Eds.), Oxford University Press, Oxford (1987).
   Google Scholar
• HARRIS MI, HADDEN WC, KNOWLER WC Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr. Diabetes (1987) 36:523–534.
   PubMed Web of Science ®Google Scholar
• 0' RAHILLY S: Science, medicine and the future. Non insulin dependent diabetes mellitus:the gathering storm. Br. Med. J. (1997) 314:955–959.
   PubMed Web of Science ®Google Scholar
• •Concise outline of the epidemiology and potential future treatments for Type 2 diabetes.
   Google Scholar
• AMOS A, MCCARTY D, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med. (1997) 14 (Suppl. 5).
   Google Scholar
• DEFRONZO RA, BONADONNA RC, FERRANNINI E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care (1992) 15:318–367.
   PubMed Web of Science ®Google Scholar
• •Important and comprehensive review.
   Google Scholar
• MORRIS AD, PETRIE JR, CONNELL JMC: Insulin and hypertension. J. Hypertens. (1994)12:633–642.
   PubMed Web of Science ®Google Scholar
• ROBBINS DC, ANDERSEN L, BOWSHER R Report of the American Diabetes Association's task force on standardisation of the insulin assay. Diabetes (1996) 45:242–256.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA, TOBIN J, ANDRES R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. (1979) 237:E214–E223.
   PubMed Web of Science ®Google Scholar
• •Key methodological paper.
   Google Scholar
• HOLLENBECK G, REAVEN GM: Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J. Clin. Endocrinol. Metab. (1987) 64:1169–1173.
   PubMed Web of Science ®Google Scholar
• REAVEN GM: Role of insulin resistance in human disease. Diabetes (1988) 37:1495–1507.
   Google Scholar
• •Seminal synthesis of mostly previously-available information on insulin resistance in asymptomatic individuals.
   Google Scholar
• FERRANNINI E, BUZZICOLI G, BONADONNA R Insulin resistance in essential hypertension. New Engl. J. Med. (1987) 317:350–357.
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate insulin resistance in essential hypertension using the euglycaemic clamp technique.
   Google Scholar
• FERRARI P, WEIDMANN P, SHAW S Altered insulin sensitivity, hyperinsulinaemia and dyslipidaemia in individuals with a hypertensive parent. Am. J. Med. (1991) 91:589–596.
   PubMed Web of Science ®Google Scholar
• HAFFNER S, MITCHELL B, VALDEZ R Eight year incidence of hypertension in Mexican-Indians and non-Hispanic whites: The San Antonio Heart Study. Am. J. Hypertens. (1992) 5:147–153.
   PubMed Web of Science ®Google Scholar
• DUNAIF A, GRAF M: Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin resistant women with the polycystic ovary syndrome. J. Clin. Invest. (1989) 83:23–29.
   PubMed Web of Science ®Google Scholar
• FRANKS S: Polycystic ovarian syndrome. New Engl. J. Med. (1995) 333:853–861.
   PubMed Web of Science ®Google Scholar
• DUNAIF A: Insulin resistance and ovarian hyperandrogenism. Endocrinologist (1992) 2:248–260.
   Google Scholar
• Koch-Weser J (Ed.), (1977) 296:787–793
   Google Scholar
• UNIVERSITY GROUP DIABETES PROGRAM: A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 19:789–830.
   PubMed Web of Science ®Google Scholar
• •Largest (flawed) published study to date examining outcomes with respect to treatment in NIDDM.
   Google Scholar
• MALMBERG K, RYDEN L, HAMSTEN A Randomised trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute MI (DIGAMI): effects on mortality at 1 year. J. Am. Coll. Cardiol. (1995) 26:57–65.
   PubMed Web of Science ®Google Scholar
• •Important recent data regarding potential deleterious effects of conventional antihyperglycaemic agents.
   Google Scholar
• MALMBERG K (THE DIGAMI GROUP): Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br. Med. J. (1997) 314:1512–1515.
   PubMed Web of Science ®Google Scholar
• BELL P, HADDEN D: Metformin: current therapies for diabetes. Endocrinol. Metab. Clin. N. Am. (1997) 26(3):523–537.
   PubMed Web of Science ®Google Scholar
• JACKSON R, HAWA M: Mechanism of metformin action in non insulin dependent diabetes. Diabetes (1987) 36:632–640.
   PubMed Web of Science ®Google Scholar
• DEFRONZO R, BARZILAI N, SIMONSON D: Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. (1991) 73:1294–1301.
   PubMed Web of Science ®Google Scholar
• GIUGLIANO D, DE ROSA N, DI MARIO G Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care (1993) 16(10):1387–1390.
   PubMed Web of Science ®Google Scholar
• DEFRONZO R, GOODMAN A: Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. New Engl. J. Med. (1995) 333:541–549.
   PubMed Web of Science ®Google Scholar
• •Two comprehensive, well-designed and clinically-relevant studies on the use of metformin.
   Google Scholar
• LUFT D, SCHMULLING RM, EGGSTEIN M: Lactic acidosis in biguanide treated diabetics. Diabetologia (1978) 14:75–87.
   PubMed Web of Science ®Google Scholar
• BAILEY C, TURNER R: Metformin. New Engl. J. Med. (1996) 334:574–578.
   PubMed Web of Science ®Google Scholar
• MEDICINES CONTROL AGENCY: Current problems in pharmacovigilance. (1997) 23:13.
   Google Scholar
• WISE J: Diabetes drug withdrawn after reports of hepatic events. Br. Med. J. (1997) 315:1564.
   PubMed Web of Science ®Google Scholar
• WATKINS P, WHITCOMB R: Hepatic dysfunction associated with troglitazone. New Engl. J. Med. (1998) 338:916–917.
   PubMed Web of Science ®Google Scholar
• HULIN B, MCCARTHY P, GIBBS EM: The glitazone family of antidiabetic agents. Curr. Pharm. Design (1996) 2:85–102.
   Web of Science ®Google Scholar
• FUJITA T, SUGIYAMA Y, TAKETOMI S Reduction of insulin resistance in obese and/or diabetic animals by 5 - (4-(1-methylcyclohexylmethoxy)-benzyl) thiazolidine-2,4-dione (ADD-3878, U-63287, ciglitazone), a new antidiabetic agent. Diabetes (1983) 32:804–810.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• •Clear basic and clinical review written prior to emergence of toxicity problems.
   Google Scholar
• STEVENSON RW, HUTSON NJ, KRUPP MN Actions of novel antidiabetic agent englitazone in hyperglycaemic ob/ob mice. Diabetes (1990) 39:1218–1227.
   PubMed Web of Science ®Google Scholar
• IBRAHIMI A, TEBOUL L, GAILLARD D Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. (1994) 46:1070–1076.
   PubMed Web of Science ®Google Scholar
• SCHOONJANS K, STAELS B, AUWERX J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta (1996) 1302:93–109.
   PubMed Web of Science ®Google Scholar
• ••Good review of a rapidly-developing field.
   Google Scholar
• TONTONZ P, HU E, SPIEGELMAN BM: Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Gen. Dev. (1995) 5:571–576.
   PubMed Web of Science ®Google Scholar
• LAMBE KG, TUGWOOD JD: The human peroxisome-proliferator-activated receptor gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. (1996) 239:1–7.
   PubMedGoogle Scholar
• ELBRECHT A, CHEN Y, CULLINAN CA Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gammal and gamma2. Biochem. Biophys. Res. Commun. (1996) 224:431–437.
   PubMed Web of Science ®Google Scholar
• •Description of PPARy expression in skeletal muscle.
   Google Scholar
• GOULD G: Facilitative glucose transporters. In: Molecular Biology Intelligence Unit. Springer,New York (1997).
   Google Scholar
• CHAIKEN RL, ECKERT-NORTON M, PASMANTIER R Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects. Diabetologia (1995) 38:1307–1312.
   PubMed Web of Science ®Google Scholar
• SUTER SL, NOLAN JJ, WALLACE P: Metabolic effects of new oral hypoglycaemic agent CS-045 in type 2 diabetes subjects. Diabetes Care (1992) 15:193–202.
   PubMed Web of Science ®Google Scholar
• •First study in human Type 2 diabetics with thiazolidinediones.
   Google Scholar
• KUMAR S, BOULTON AJM, BECK-NIELSEN H Troglitazone, an insulin enhancer, improves metabolic control in type 2 diabetes patients. Diabetologia (1996) 39:701–709.
   PubMed Web of Science ®Google Scholar
• IVVAMOTO Y, KOSAKA K, KUZUYA T Effect of combination therapy of troglitazone and sulfonylureas in patients with type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabetic Med. (1996) 13:365–370.
   PubMed Web of Science ®Google Scholar
• INZUCCHI SE, MAGGS DG, SPOLLETT GR Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl. J. Med. (1998) 338:867–872.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ S, RASKIN P, FONSECA V Effect of troglitazone in insulin treated patients with type II diabetes mellitus. New Engl. J. Med. (1998) 338:861–866.
   PubMed Web of Science ®Google Scholar
• HARRIS MI: Impaired glucose tolerance in the US population. Diabetes Care (1989) 12:464–474.
   PubMed Web of Science ®Google Scholar
• ANTONUCCI T, MCLAIN R, WHITCOMB R, LOCKWOOD D: Impaired glucose toleranceis normalised by treatment with the thiazolidinedione, troglitazone. Diabetes Care (1997) 20:188–193.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ K, PETERS R, KJOS SL Effect of troglitazone on insulin sensitivity andpancreatic beta cell function in women at high risk for type 2 diabetes. Diabetes (1996) 45:1572–1579.
   PubMed Web of Science ®Google Scholar
• LAW R, MEEHAN W, XI X-P Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. (1996) 98:1897–1905.
   PubMed Web of Science ®Google Scholar
• DUBEY R, ZHANG H, REDDY S Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. (1993) 265:R726–R732.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA S, NISHINO H, SHIRAKI T Antihypertensive effect of CS-045 treatment in obese Zucker rats. Metabolism (1993) 42(1) :75–80.
   PubMed Web of Science ®Google Scholar
• SIRONI A, VICHI S, GASALDELLI A Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin. Pharmacol. Ther. (1997) 62:194–202.
   PubMed Web of Science ®Google Scholar
• HOWARD G, O'LEARY D, ZACCARO D: Insulin sensitivity and atherosclerosis. Circulation (1996) 93:1809–1817.
   PubMed Web of Science ®Google Scholar
• •One of the largest studies to include validated insulin sensitivity data (measured by the iv. glucose tolerance test).
   Google Scholar
• DUNAIF A, SCOTT D, FINEGOOD D The insulin sensitising agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1996) 81:3299–3306.
   PubMed Web of Science ®Google Scholar
• EHRMANN D, SCHNEIDER D, SOBEL B Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. (1997) 82:2108–2116.
   PubMed Web of Science ®Google Scholar
• MAYFIELD R, MCLEAN D, CROOK D CS-045 toxicity to the cynomolgus monkeys by repeated oral administration for 52 weeks. J. Clin. Ther. Med. (1993) 9 (Suppl. 3) :317–341.
   Google Scholar
• GHAZZI M, PEREZ J,ANTONUCCI T Cardiac and glycaemic benefits of troglitazone treatment in type 2 diabetes. Diabetes (1997) 46:433–439.
   PubMed Web of Science ®Google Scholar
• ANDERSON R, CHENG N, BRYDEN N Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes (1997) 46:1786–1791.
   PubMed Web of Science ®Google Scholar
• KATO K, NAKAYAMA K, OHTA M Effects of novel aldose reductase inhibitors M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur. J. Pharmacol. (1991) 193:185–191.
   PubMed Web of Science ®Google Scholar
• NICOLUCCI A, CARINCI F, CAVALIERE D A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. Diabetic Med. (1996) 12:1017–1026.
   Web of Science ®Google Scholar
• NAKAYAMA K, MURAKAMI N, OHTA M Antihyperglycaemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats. Eur. J. Pharmacol. (1995) 276:77–83.
   PubMed Web of Science ®Google Scholar
• OHTA M, MURAKAMI M, KATO K Effects of M16209, a new antihyperglycaemicagent, on insulin sensitivity in vivo: euglycaemic clamp studies in rats. Metabolism (1996) 4:1095–1100.
   Web of Science ®Google Scholar
• MURAKAMIN, OHTA M, HASHIMOTO K Amelioration of insulin resistance ingenetically obese rodents by M16209, a new antidiabetic agent. Eur. J. Pharmacol. (1996) 304:129–134.
   PubMed Web of Science ®Google Scholar
• KROTKIEWSKI M, MANDROUKAS K, SJOSTROM L Effects of long-term physicaltraining on body fat, metabolism and blood pressure in obesity. Metabolism (1979) 28:650–658.
   PubMed Web of Science ®Google Scholar
• PETRIE JR, DONNELLY R: New pharmacological approaches to insulin and lipid metabolism. Drugs (1994) 47:701–710.
   PubMed Web of Science ®Google Scholar
• HOLLENGMA C, ZAAGSMA J: Direct evidence for the atypical nature of functional beta-receptors in rat adipocytes. Br. J. Pharmacol. (1989) 98:1420–1424.
   PubMed Web of Science ®Google Scholar
• EMORINE JL, MARULLO S, BRIEND-SUTREN MM Molecular characterisation of thehuman beta3-adrenergic receptor. Science (1989) 245:1118–1121.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ DE, NARDONE NA, SMILEY RM Distribution of beta3-adrenoceptor mRNA in human tissues. Eur. J. Pharmacol. (Mol. Pharmacol. Section) (1995) 289:223–228.
   PubMed Web of Science ®Google Scholar
• LIPWORTH BJ: Clinical pharmacology of beta3-adrenoceptors. Br. J. Pharmacol. (1996) 42:291–300.
   Web of Science ®Google Scholar
• CAWTHORNE MA, SENNIN MV, ARCH JRS, SMITH SA: BRL35135, a potent and selective atypical beta-adrenoceptor agonist. Am. J. Clin. Nutr. (1992) 55:252S–257S.
   Google Scholar
• FISHER LG, SHER PM, SKWISH S BMS-187257, a potent, selective and novel heterocyclic beta3 adrenergic receptor agonist. Bioorg. Med. Chem. Lett. (1996) 6 (19) :2253–2258.
   Web of Science ®Google Scholar
• HIOKI Y, ITOH Y, NAKAJIMA A A novel adrenaline agent, AZ0002 and its hypoglycaemic action in yellow KK mice. Pharmacology (1995) 69(3) :251.
   Web of Science ®Google Scholar
• UNITED KINGDOM PROSPECTIVE DIABETES STUDY GROUP: UKPDS 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br. Med. J. (1995) 310:83–88.
   PubMed Web of Science ®Google Scholar
• CHIASSON J-L, JOSSE RG, HUNT JA The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. Ann. Intern. Med. (1995) 98:443–451.
   Google Scholar